

## COMPANY ANNOUNCEMENT

### ASIC issues interim order in relation to Living Cell Technologies' Prospectus



**5 July 2004, Australia:** On 2 July 2004 the Australian Securities and Investments Commission ("**ASIC**") notified Living Cell Technologies Limited (NSX:LCT) ("**LCT**") that ASIC had made an interim order pursuant to Section 739(3) of the Corporations Act in relation to LCT's Prospectus dated 14 May 2004. The order prevents offers, issues, sales or transfers of securities being made under the Prospectus and it lasts for 21 days unless revoked before then.

LCT is actively liaising with ASIC to address ASIC's concerns and to ensure that the interim order is revoked as soon as possible. At present, LCT considers that it will need to issue a supplementary prospectus to address the disclosure issues raised by ASIC, and expects to lodge such a document with ASIC shortly.

#### ENDS

---

#### About LCT

LCT is an NSX listed biotechnology company.

LCT's business was formed in 1987, and has been built around a uniquely novel and patented technology platform which has versatile applications, diverse relevance and the potential for multiple revenue streams.

LCT, which developed and owns its originating intellectual property, operates through wholly-owned subsidiaries. Its corporate head office and scientific panel is based in Adelaide, its research and technology unit is based in Auckland, New Zealand and its product development and regulatory unit is based in Rhode Island, United States.

LCT focuses on treatment for diseases that are currently not being well managed and currently have no cure, such as Huntington's disease, Haemophilia and Diabetes. This market-driven approach puts LCT in a unique position to offer alternative treatments for those diseases. LCT has demonstrated early success of its technology platform in authorised pilot human trials conducted in New Zealand and, following completion of the fundraising announced above, intends to embark on pre-clinical trials of its product portfolio to support registration and commercialisation of its patented cell based treatments.

For more information about LCT, visit [www.lct.com.au](http://www.lct.com.au)

| Media Information  | Company Information  |  |
|--|--|--|
| Kate Mazoudier   | David Collinson CEO  | Roger Coats COO  |
| Buchan   | Living Cell Technologies Ltd                                       | Living Cell Technologies Ltd                               |
| Tel: +61 3 9866 4722   | Tel: +618 8179 2874  | Tel: +618 8179 2874  |
| Mobile +61 403 497 424   | Mobile +61 402 716 984   | Fax: +618 8179 2885  |
| <a href="mailto:kmazoudier@bcg.com.au">kmazoudier@bcg.com.au</a> | <a href="mailto:d.collinson@lct.com.au">d.collinson@lct.com.au</a> | <a href="mailto:r.coats@lct.com.au">r.coats@lct.com.au</a> |